<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02651454</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2015_OBESITY</org_study_id>
    <nct_id>NCT02651454</nct_id>
  </id_info>
  <brief_title>A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -</brief_title>
  <official_title>A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Oriental Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sangji University Oriental Medical Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DongGuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Oriental Medical Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this trial is to investigate the efficacy and safety of Daesiho-tang and
      Taeeumjowi-tang on Korean obese Women with metabolic syndrome Risk factors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in body weight</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body fat percentage</measure>
    <time_frame>baseline, 4,8,12,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in fat mass</measure>
    <time_frame>baseline, 4,8,12,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Waist circumference</measure>
    <time_frame>baseline, 4,8,12,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Waist/hip ratio</measure>
    <time_frame>baseline, 4,8,12,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Body mass index</measure>
    <time_frame>baseline, 4,8,12,16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Lipid profile</measure>
    <time_frame>Screening visit, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in C-reactive protein (CRP)</measure>
    <time_frame>Screening visit, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood glucose</measure>
    <time_frame>Screening visit, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in abdominal visceral fat area</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean Obesity-related Quality of Life (QoL) scale</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean version of Eating Attitudes Test-26</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Daesiho-tang</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 6g, three times a day, each taken before or between meals for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jowiseungcheung-tang</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose: 6g, three times a day, each taken before or between meals for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose: 6g, three times a day, each taken before or between meals for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daesiho-tang</intervention_name>
    <description>Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>Daesiho-tang</arm_group_label>
    <other_name>DST</other_name>
    <other_name>Elsion Granule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jowiseungcheung-tang</intervention_name>
    <description>Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.</description>
    <arm_group_label>Jowiseungcheung-tang</arm_group_label>
    <other_name>JWSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged 18 to 65 years

          -  Subject must included at least one or more of the following symptoms below

               -  BMI of 30 kg/㎡ or more;

               -  BMI between 25 and 29.9kg/㎡ with hypertension, taking medication or SBP ≥ 140mmHg
                  or DBP ≥ 90mmHg at the screening visit

               -  BMI between 25 and 29.9kg/㎡ with non-insulin-dependent diabetes mellitus, taking
                  medication or fasting blood glucose &gt; 126mg/dL at the screening visit

               -  BMI between 25 and 29.9kg/㎡ with hyperlipidemia, taking medication or total
                  cholesterol ≥ 200mg/dL or Triglyceride ≥ 150mg/dL at screening visit

          -  Agreed to low-calorie diet during the trial

          -  Written informed consent of the trial

        Exclusion Criteria:

          -  Endocrine diseases associated with weight gain, such as hypothyroidism, Cushing's
             syndrome, etc.

          -  Heart disease (heart failure, angina pectoris, myocardial infarction)

          -  Cholelithiasis

          -  Severe renal disability (SCr &gt; 2.0 mg/dL)

          -  Severe liver disability (2.5 fold of normal high range value on Alanine
             Aminotransferase [ALT], Aspartate Aminotransferase [AST], alkaline phosphatase)

          -  History of narrow angle glaucoma

          -  History of stroke or temporary ischemic cardioplegia

          -  History of eating disorder such as anorexia nervosa or bulimia nervosa, etc.

          -  Use of medication that can affect on weight within last 3 months (appetite
             suppressant, laxative, oral steroid, thyroid hormone, amphetamine, cyproheptadine,
             phenothiazine or medications can affect on absorption, metabolism, excretion)

          -  Use of CNS stimulant medication for weight loss

          -  Forbidden treatment (Insulin, hypoglycemic agent, antidepressant, antiserotonin agent,
             barbiturate, antipsychotic, medication concerns of abuse)

          -  history of weight loss surgery, such as bariatric surgery, etc.

          -  Subjects who are judged to be inappropriate for the clinical study by the researchers

          -  Women who were pregnant, lactating or have the chances of pregnancy who do not agree
             to proper contraception (birth-control pill, hormone implant, IUD, spermicide, condom,
             abstinence, etc.)

          -  Use of other investigational product within last 1 month

          -  10 percent reduction in body weight over 6 months

          -  Decided to quit smoking over the last 3 months or have irregular smoking habits
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yun-Kyung Song, KMD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Oriental Medical Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youme Ko, MD(TCM)</last_name>
    <phone>8229619278</phone>
    <email>meyougo@khu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon University Gil Oriental Medical Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, Chang-Hyun Park, KMD</last_name>
      <phone>82327701300</phone>
      <email>chpark104@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2016</study_first_submitted>
  <study_first_submitted_qc>January 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2016</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Oriental Medical Hospital</investigator_affiliation>
    <investigator_full_name>Yun-Kyung Song</investigator_full_name>
    <investigator_title>KMD, PhD</investigator_title>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>Daesiho-tang</keyword>
  <keyword>Taeeumjowi-tang</keyword>
  <keyword>Korean medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

